Albireo
Clinical trials sponsored by Albireo, explained in plain language.
-
New drug shows promise for fatty liver – but early days
Disease control CompletedThis phase 2 trial tested elobixibat, a drug that blocks bile acid absorption in the gut, in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form NASH. Participants received either elobixibat or a placebo for 16 weeks. The main goal was to see if the dr…
Phase: PHASE2 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug shows promise for rare childhood liver disease
Disease control CompletedThis study tested a drug called odevixibat (A4250) in 62 children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2, a rare liver disease that causes severe itching and bile buildup. The drug works by blocking the reabsorption of bile acids in the gut. The g…
Phase: PHASE3 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC